Literature DB >> 15805704

Chronic kidney disease as a metabolic syndrome with malnutrition--need for strict control of risk factors.

Tetsuo Shoji1, Yoshiki Nishizawa.   

Abstract

Patients with chronic kidney disease (CKD) have an increased risk for death from cardiovascular disease (CVD). They have multiple metabolic abnormalities that may accelerate atherosclerosis, such as hypertension, insulin resistance, and dyslipidemia, along with other CKD-related risk factors. In addition, a considerable proportion of patients with advanced stages of CKD are malnourished, presenting "metabolic syndrome with malnutrition". The presence of malnutrition/inflammation dramatically changes the apparent relationship between CVD death risk and some risk factors. For example, in stage 5 CKD patients on hemodialysis, a higher body mass index and a higher plasma cholesterol are predictors of better survival. To understand the paradoxic epidemiology, we should recognize risk factors for occurrence of CVD events and risk factors of fatality after an event. In this article, we review the unique situation of CKD, emphasizing the need of more strict control of both types of risk factors to improve survival of CKD patients.

Entities:  

Mesh:

Year:  2005        PMID: 15805704     DOI: 10.2169/internalmedicine.44.179

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  9 in total

1.  Elevated non-high-density lipoprotein cholesterol (non-HDL-C) predicts atherosclerotic cardiovascular events in hemodialysis patients.

Authors:  Tetsuo Shoji; Ikuto Masakane; Yuzo Watanabe; Kunitoshi Iseki; Yoshiharu Tsubakihara
Journal:  Clin J Am Soc Nephrol       Date:  2011-04-21       Impact factor: 8.237

Review 2.  Clinical assessment and management of dyslipidemia in patients with chronic kidney disease.

Authors:  Kosaku Nitta
Journal:  Clin Exp Nephrol       Date:  2012-06-22       Impact factor: 2.801

Review 3.  Serum lipids and prevention of atherosclerotic cardiovascular events in hemodialysis patients.

Authors:  Tetsuo Shoji
Journal:  Clin Exp Nephrol       Date:  2013-09-27       Impact factor: 2.801

4.  The effect of recombinant human erythropoietin treatment on insulin resistance and inflammatory markers in non-diabetic patients on maintenance hemodialysis.

Authors:  Z Rasic-Milutinovic; G Perunicic-Pekovic; A Cavala; Z Gluvic; L Bokan; S Stankovic
Journal:  Hippokratia       Date:  2008-07       Impact factor: 0.471

5.  Effects of Oral L-Carnitine Supplementation on Lipid Profile, Anemia, and Quality of Life in Chronic Renal Disease Patients under Hemodialysis: A Randomized, Double-Blinded, Placebo-Controlled Trial.

Authors:  Afsoon Emami Naini; Mahnaz Moradi; Mojgan Mortazavi; Asghar Amini Harandi; Mehdi Hadizadeh; Farhad Shirani; Hamed Basir Ghafoori; Pardis Emami Naini
Journal:  J Nutr Metab       Date:  2012-06-05

6.  Comparative effectiveness of incident oral antidiabetic drugs on kidney function.

Authors:  Adriana M Hung; Christianne L Roumie; Robert A Greevy; Xulei Liu; Carlos G Grijalva; Harvey J Murff; T Alp Ikizler; Marie R Griffin
Journal:  Kidney Int       Date:  2012-01-18       Impact factor: 10.612

7.  Increased blood pressure in adult offspring of families with Balkan endemic nephropathy: a prospective study.

Authors:  Plamen S Dimitrov; Valeri A Simeonov; Svetlana D Tsolova; Angel G Bonev; Rossitza B Georgieva; Wilfried J Karmaus
Journal:  BMC Nephrol       Date:  2006-08-23       Impact factor: 2.388

8.  Low calf circumference can predict nutritional risk and mortality in adults with metabolic syndrome aged over 80 years.

Authors:  Chenxi Ren; Xiaoyan Zhang; Yunxia Zhu; Jun Xu; Ying Xie
Journal:  BMC Endocr Disord       Date:  2022-02-23       Impact factor: 2.763

9.  Associations of Serum Insulin-Like Growth Factor 1 with New Cardiovascular Events and Subsequent Death in Hemodialysis Patients: The DREAM Cohort.

Authors:  Rino Nakaya; Tetsuo Shoji; Yuki Nagata; Shinya Nakatani; Katsuhito Mori; Tomoaki Morioka; Yoshihiro Tsujimoto; Masanori Emoto
Journal:  J Atheroscler Thromb       Date:  2021-09-11       Impact factor: 4.394

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.